These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2960958)

  • 21. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():86-92. PubMed ID: 2533160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged suppression of rat testis function by a depot formulation of Zoladex, a GnRH agonist.
    Ward JA; Furr BJ; Valcaccia B; Curry B; Bardin CW; Gunsalus GL; Morris ID
    J Androl; 1989; 10(6):478-86. PubMed ID: 2533593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
    Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
    Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
    Ryan PG; Peeling WB
    Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
    Peeling WB
    Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of long-acting LHRH analog (Zoladex) on prostate cancer: evaluated by transrectal ultrasonography.
    Drago JR; Nesbitt JA; Cirulli C
    Urology; 1988 Oct; 32(4):285-7. PubMed ID: 2972104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
    Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
    Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
    West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
    Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
    Furr BJ; Hutchinson FG
    Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
    [No Abstract]   [Full Text] [Related]  

  • 32. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
    Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
    Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C; Denis L
    Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
    Fernandez del Moral P; Litjens TT; Weil EH; Debruyne FM
    Urology; 1988 Aug; 32(2):137-40. PubMed ID: 2969641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary treatment of advanced cancer of the prostate with Zoladex.
    Klarskov P; Lund F; Petersen SE
    Int Urol Nephrol; 1990; 22(4):359-62. PubMed ID: 2146234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group.
    Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
    Eur Urol; 1995; 27(1):43-6. PubMed ID: 7744141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
    Mahler C; Verhelst J; Chaban M; Denis L
    Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of metastatic prostate carcinoma with the depot LRH analog Zoladex.
    Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; List A; Rutland M; Knox BS
    Prostate; 1988; 12(2):119-27. PubMed ID: 2966931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
    Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B
    Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.